Metastatic prostate cancer

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · see citing works

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · see citing works

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · see citing works

Abiraterone and Increased Survival in Metastatic Prostate Cancer

de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · see citing works

Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate

Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856 · see citing works

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Petrylak, D. P., Tangen, C. M., Hussain, M., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D. L., Moinpour, C. M., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665 · see citing works

Integrative Clinical Genomics of Advanced Prostate Cancer

Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645 · see citing works

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · see citing works

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318 · see citing works

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028 · see citing works

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Sweeney, C. J., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., Wong, Y., Hahn, N. M., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,908 · see citing works

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796 · see citing works

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710 · see citing works

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Fizazi, K. S., Tran, N., Fein, L. E., Matsubara, N., Rodríguez-Antolín, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,326 · see citing works

Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292 · see citing works

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185 · see citing works

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,983 · see citing works

Abiraterone for prostate cancer not previously treated with hormone therapy

James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801 · see citing works

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680 · see citing works

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P. P., White, T. A., Stojanov, P., Allen, E. M. V., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,550 · see citing works

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369 · see citing works

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C. H., Koutcher, J. A., Scher, H. I., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,197 · see citing works

Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence

Matsuo, H., Baba, Y., Nair, R. M. G., Arimura, A., & Schally, A. V. (1971) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(71)80019-0 · Cited by 1,194 · see citing works

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

Ku, S., Rosario, S. R., Wang, Y., Mu, P., Seshadri, M., Goodrich, Z., Goodrich, M. M., Labbé, D. P., Gomez, E. C., Wang, J., et al. (2017) · Science · doi:10.1126/science.aah4199 · Cited by 1,093 · see citing works

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903 · see citing works

German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Rahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M. A., Essler, M., Baum, R. P., Kulkarni, H., Schmidt, M. C., Drzezga, A. E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 849 · see citing works

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748 · see citing works

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

Scher, H. I., Lu, D. M., Schreiber, N. A., Louw, J. E., Graf, R. P., Vargas, H. A., Johnson, A. D., Jendrisak, A., Bambury, R. M., Danila, D. C., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1828 · Cited by 643 · see citing works

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression

Whang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., SAID, J. W., Isaacs, W. B., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5246 · Cited by 639 · see citing works

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Antonarakis, E. S., Lu, C., Luber, B. S., Wang, H., Chen, Y., Nakazawa, M., Nadal, R., Paller, C. J., Denmeade, S. R., Carducci, M. A., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1341 · Cited by 618 · see citing works

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

Attard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0642 · Cited by 605 · see citing works

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding

Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505 · see citing works

Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

Halabi, S., Lin, C., Kelly, W. K., Fizazi, K. S., Moul, J. W., Kaplan, E. B., Morris, M. J., & Small, E. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3696 · Cited by 479 · see citing works

Plasma AR and abiraterone-resistant prostate cancer

Romanel, A., Tandefelt, D. G., Conteduca, V., Jayaram, A., Casiraghi, N. A., Wetterskog, D., Salvi, S., Amadori, D., Zafeiriou, Z., Rescigno, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9511 · Cited by 437 · see citing works

Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

Tagawa, S. T., Milowsky, M. I., Morris, M. J., Vallabhajosula, S., Christos, P. J., Akhtar, N. H., Osborne, J. R., Goldsmith, S. J., Larson, S. M., Taskar, N. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0231 · Cited by 427 · see citing works

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Evans, C. P., Kim, C., Kimura, G., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.07.032 · Cited by 426 · see citing works

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

Vale, C. L., Burdett, S., Rydzewska, L. H. M., Albiges, L. K., Clarke, N. W., Fisher, D. J., Fizazi, K. S., Gravis, G., James, N. D., Mason, M. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00489-1 · Cited by 406 · see citing works

Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis

Mannweiler, S., Amersdorfer, P., Trajanoski, S., Terrett, J. A., King, D., & Méhes, G. (2008) · Pathology & Oncology Research · doi:10.1007/s12253-008-9104-2 · Cited by 386 · see citing works

Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer

Scher, H. I., Heller, G., Molina, A., Attard, G., Danila, D. C., Jia, X., Peng, W., Sandhu, S. K., Olmos, D., Riisnaes, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3487 · Cited by 380 · see citing works

Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer

Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00013a022 · Cited by 379 · see citing works

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer

Wyatt, A. W., Azad, A., Volik, S. V., Annala, M., Beja, K., McConeghy, B. J., Haegert, A. M., Warner, E. W., Mo, F., Brahmbhatt, S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0494 · Cited by 372 · see citing works

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Graff, J. N., Alumkal, J. J., Drake, C. G., THOMAS, G. V., Redmond, W. L., Farhad, M. E., Cetnar, J. P., Ey, F. S., Bergan, R. C., Slottke, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10547 · Cited by 360 · see citing works

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA

Oudard, S. M., Fizazi, K. S., Sengeløv, L., Daugaard, G., Fred Saad, C., Hansen, S., Hjälm-Eriksson, M., Jassem, J., Thiery-Vuillemin, A., Caffo, O., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1068 · Cited by 357 · see citing works

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

Noonan, K. L., North, S., Bitting, R. L., Armstrong, A. J., Ellard, S. L., & Chi, K. N. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt138 · Cited by 343 · see citing works

Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death

Na, R., Zheng, S. L., Han, M., Yu, H., Jiang, D., Shah, S., Ewing, C. M., Zhang, L., Novakovic, K. R., Petkewicz, J., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.11.033 · Cited by 343 · see citing works

Can Whole-body Magnetic Resonance Imaging with Diffusion-weighted Imaging Replace Tc 99m Bone Scanning and Computed Tomography for Single-step Detection of Metastases in Patients with High-risk Prostate Cancer?

Lecouvet, F. E., Mouedden, J. E., Collette, L., Coche, E., Danse, E. M., Jamar, F., Machiels, J., Berg, B. V., Omoumi, P., & TOMBAL, B. F. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.020 · Cited by 301 · see citing works

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m 2 ) and the Currently Approved Dose (25 mg/m 2 ) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA

Eisenberger, M. A., Bessard, A. C. H., Kim, C., Géczi, L., Ford, D., Mourey, L., Carles, J., Parente, P., Pous, A. F., Kacsó, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1076 · Cited by 292 · see citing works

Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone

Schrader, A. J., Boegemann, M., Ohlmann, C.-H., Schnoeller, T. J., Krabbe, L., Hajili, T., Jentzmik, F., Stöeckle, M., Schrader, M. G., Herrmann, E., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.06.042 · Cited by 283 · see citing works

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer

Pritchard, C. C., Morrissey, C. M., Kumar, A., Zhang, X., Smith, C., Coleman, I. M., Salipante, S. J., Milbank, J. H., Yu, M., Grady, W. M., et al. (2014) · Nature Communications · doi:10.1038/ncomms5988 · Cited by 269 · see citing works

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Conteduca, V., Wetterskog, D., Sharabiani, M. T. A., Grande, E., Fernández-Pérez, M. P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx155 · Cited by 269 · see citing works

Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer

Cheng, H. H., Pritchard, C. C., Boyd, T. E., Nelson, P. S., & Montgomery, B. (2015) · European Urology · doi:10.1016/j.eururo.2015.11.022 · Cited by 262 · see citing works

Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer

Li, Z., Bishop, A. C., Alyamani, M., Garcia, J. A., Dreicer, R., Bunch, D. R., Liu, J., Upadhyay, S. K., Auchus, R. J., & Sharifi, N. (2015) · Nature · doi:10.1038/nature14406 · Cited by 258 · see citing works

The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer

Pomerantz, M. M., Spisák, S., Li, J., Cronin, A. M., Csabai, I., Ledet, E. M., Sartor, O. A., Rainville, I. R., O’Connor, E. P., Herbert, Z. T., et al. (2017) · Cancer · doi:10.1002/cncr.30808 · Cited by 257 · see citing works

Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic

Auchus, R. J. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.02.002 · Cited by 233 · see citing works

Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients

Lallous, N., Volik, S. V., Awrey, S. J., Leblanc, E., Tse, R., Murillo, J., Singh, K., Azad, A., Wyatt, A. W., LeBihan, S., et al. (2016) · Genome biology · doi:10.1186/s13059-015-0864-1 · Cited by 208 · see citing works

SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K/mTOR and AR signaling

Blattner, M., Liu, D., Robinson, B. D., Huang, D., Poliakov, A., Gao, D., Nataraj, S., Deonarine, L. D., Augello, M. A., Sailer, V., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.004 · Cited by 204 · see citing works

Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes

Xu, D., Zhan, Y., Qi, Y., Cao, B., Bai, S., Xu, W., Gambhir, S. S., Lee, P., Sartor, O. A., Flemington, E. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0381 · Cited by 190 · see citing works

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

Lecarpentier, J., Silvestri, V., Kuchenbaecker, K. B., Barrowdale, D., Dennis, J., McGuffog, L., Soucy, P., Leslie, G., Rizzolo, P., Navazio, A. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.4935 · Cited by 179 · see citing works

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials

van Soest, R. J., Templeton, A. J., Vera-Badillo, F., Mercier, F., Sonpavde, G., Amir, E., TOMBAL, B. F., Rosenthal, M. A., Eisenberger, M. A., Tannock, I. F., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu569 · Cited by 141 · see citing works

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data

Guinney, J., Wang, T., Laajala, T. D., Winner, K. K., Bare, J. C., Neto, E. C., Khan, S. A., Peddinti, G., Airola, A., Pahikkala, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30560-5 · Cited by 136 · see citing works

Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer

Fitzpatrick, J. M., & de Wit, R. (2013) · European Urology · doi:10.1016/j.eururo.2013.07.022 · Cited by 135 · see citing works

Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results

Morris, M. J., Molina, A., Small, E. J., Bono, J. S. D., Logothetis, C. J., Fizazi, K. S., SOUZA, P. D., Kantoff, P. W., Higano, C. S., Li, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3875 · Cited by 133 · see citing works

Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy

Sun, M., Choueiri, T. K., Hamnvik, O. R., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4917 · Cited by 123 · see citing works

PSMA PET and Radionuclide Therapy in Prostate Cancer

Bouchelouche, K., Türkbey, B., & Choyke, P. L. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.07.006 · Cited by 101 · see citing works

Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

Bono, J. S. D., Smith, M. R., Fred Saad, C., Rathkopf, D. E., Mulders, P., Small, E. J., Shore, N. D., Fizazi, K. S., Porre, P. D., Kheoh, T. S., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.033 · Cited by 79 · see citing works

Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer

Ho, Y., & Dehm, S. M. (2017) · Endocrinology · doi:10.1210/en.2017-00109 · Cited by 73 · see citing works

PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)

Bono, J. S. D., Giorgi, U. D., Massard, C., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw372.02 · Cited by 55 · see citing works

Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

Hansen, A. R., Massard, C., Ott, P. A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw372.09 · Cited by 48 · see citing works

Clinical Outcomes from Androgen Signaling–directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

Smith, M. R., Fred Saad, C., Rathkopf, D. E., Mulders, P., Bono, J. S. D., Small, E. J., Shore, N. D., Fizazi, K. S., Kheoh, T. S., Li, J., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.007 · Cited by 43 · see citing works

Radiolabeled prostate-specific membrane antigen small-molecule inhibitors

Will, L., Sonni, I., Kopka, K., Kratochwil, C., Giesel, F. L., & Haberkorn, U. (2017) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.17.02977-6 · Cited by 24 · see citing works

Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone

Gill, D. M., Gaston, D. C., Bailey, E. B., Hahn, A. W., Gupta, S. V., Batten, J. A., Alex, A. B., Boucher, K. M., Stenehjem, D. D., & Agarwal, N. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.12.008 · Cited by 20 · see citing works

Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476)

Sydes, M. R., Mason, M. D., Spears, M. R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.024 · Cited by 19 · see citing works

Clinical versus radiographic progression and overall survival for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from COU-AA-302.

Ryan, C. J., Kheoh, T. S., Scher, H. I., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.6_suppl.193 · Cited by 1 · see citing works

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864 · see citing works

Olaparib for Metastatic Castration-Resistant Prostate Cancer

de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323 · see citing works

Il-23 secreted by myeloid cells drives castration-resistant prostate cancer

Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., Mirenda, M., Pasquini, E., et al. (2018) · Nature · doi:10.1038/s41586-018-0266-0 · Cited by 394 · see citing works

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01653-2 · Cited by 362 · see citing works

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

Seifert, R., Kessel, K., Schlack, K., Weber, M., Herrmann, K., Spanke, M., Fendler, W. P., Hadaschik, B., Kleesiek, J., Schäfers, M., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05040-1 · Cited by 160 · see citing works

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

Fizazi, K., Herrmann, K., Krause, B. J., Rahbar, K., Chi, K. N., Morris, M. J., Sartor, O., Tagawa, S. T., Kendi, A. T., Vogelzang, N., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00158-4 · Cited by 125 · see citing works

HER3 Is an Actionable Target in Advanced Prostate Cancer

Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D’Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-3360 · Cited by 68 · see citing works

Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives

Ruiz de Porras, V., Font, A., & Aytes, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.033 · Cited by 65 · see citing works

Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy

Labrie, F., Bélanger, A., Simard, J., Labrie, C., & Dupont, A. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+ · Cited by 93 · see citing works

Androgen Deprivation Therapy with Chemotherapy or Abiraterone for Patients with Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis

Sun, G., Chen, X., X, Gong, U., Chen, Y., Li, G., Wei, F., Jiang, A., Niu, Y., & Shang, Z. (2019) · Future Oncology · doi:10.2217/fon-2018-0619 · Cited by 9 · see citing works

Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen‐deprivation therapy

Bao, B., Pao, J.-B., Huang, C., Pu, Y., Chang, T.-Y., Lan, Y., Lu, T., Lee, H., Chen, L., Ting, W., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26091 · Cited by 24 · see citing works

Role of somatostatin receptor SSRT5-AS1 in predicting biomarkers of primary androgen deprivation therapy on prostate cancer in Indonesian population.

Soerohardjo, I., Widodo, I., Zulfiqqar, A., et al. (2022) · PubMed

Circulating cell-free DNA is a potential prognostic biomarker of metastatic castration-resistant prostate cancer for taxane therapy

Mei, W., Gu, Y. J., Jiang, Y., et al. (2018) · AME Medical Journal · doi:10.21037/amj.2018.06.01 · Cited by 5 · see citing works